Development of novel non-invasive diagnostic tests to detect lymphomas
LyMoDx will deliver a novel in vitro diagnostic (IVD) test to detect cancer in blood. Cells release extracellular vesicles (EV) containing distinct RNA fingerprints into the blood; the EV-based RNA fingerprint for lymphoma will be technically validated, tested in a proof-of-concept study and offered as a diagnostic service to pharma, while being further developed into an in vitro diagnostic test (IVD). The consortium will perform full clinical studies directly after the project end.
3 059 130.00€